• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非小细胞肺癌中的突变发生率和一致性:基于种族和组织学的荟萃分析(mutMap)。

Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap).

机构信息

R&D Genetics, Personalised Healthcare & Biomarkers, AstraZeneca, Macclesfield, UK.

出版信息

Ann Oncol. 2013 Sep;24(9):2371-6. doi: 10.1093/annonc/mdt205. Epub 2013 May 30.

DOI:10.1093/annonc/mdt205
PMID:23723294
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3755331/
Abstract

BACKGROUND

Meta-analyses were conducted to characterize patterns of mutation incidence in non small-cell lung cancer (NSCLC).

DESIGN

Nine genes with the most complete published mutation coincidence data were evaluated. One meta-analysis generated a 'mutMap' to visually represent mutation coincidence by ethnicity (Western/Asian) and histology (adenocarcinoma [ADC] or squamous cell carcinoma). Another meta-analysis evaluated incidence of individual mutations. Extended analyses explored incidence of EGFR and KRAS mutations by ethnicity, histology, and smoking status.

RESULTS

Genes evaluated were TP53, EGFR, KRAS, LKB1, EML4-ALK, PTEN, BRAF, PIK3CA, and ErbB2. The mutMap highlighted mutation coincidences occurring in ≥5% of patients, including TP53 with KRAS or EGFR mutations in patients with ADC, and TP53 with LKB1 mutation in Western patients. TP53 was the most frequently mutated gene overall. Frequencies of TP53, EGFR, KRAS, LKB1, PTEN, and BRAF mutations were influenced by histology and/or ethnicity. Although EGFR mutations were most frequent in patients with ADC and never/light smokers from Asia, and KRAS mutations were most frequent in patients with ADC and ever/heavy smokers from Western countries, both were detected outside these subgroups.

CONCLUSIONS

Potential molecular pathology segments of NSCLC were identified. Further studies of mutations in NSCLC are warranted to facilitate more specific diagnoses and guide treatment.

摘要

背景

进行荟萃分析以描述非小细胞肺癌(NSCLC)中突变发生率的模式。

设计

评估了具有最完整已发表突变一致性数据的九个基因。一项荟萃分析生成了一个“mutMap”,通过种族(西方/亚洲)和组织学(腺癌[ADC]或鳞状细胞癌)来直观地表示突变一致性。另一项荟萃分析评估了个体突变的发生率。扩展分析探讨了 EGFR 和 KRAS 突变在种族、组织学和吸烟状态下的发生率。

结果

评估的基因包括 TP53、EGFR、KRAS、LKB1、EML4-ALK、PTEN、BRAF、PIK3CA 和 ErbB2。mutMap 突出显示了在≥5%的患者中发生的突变一致性,包括在 ADC 患者中存在 TP53 与 KRAS 或 EGFR 突变,以及在西方患者中存在 TP53 与 LKB1 突变。TP53 是总体上最常突变的基因。TP53、EGFR、KRAS、LKB1、PTEN 和 BRAF 突变的频率受组织学和/或种族的影响。尽管 EGFR 突变在亚洲从不吸烟/轻度吸烟的 ADC 患者中最常见,KRAS 突变在西方从不吸烟/重度吸烟的 ADC 患者中最常见,但这两种突变在这些亚组之外都有检测到。

结论

确定了 NSCLC 的潜在分子病理学亚组。需要进一步研究 NSCLC 中的突变,以促进更具体的诊断并指导治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d27/3755331/a705e58c0465/mdt20501.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d27/3755331/a705e58c0465/mdt20501.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d27/3755331/a705e58c0465/mdt20501.jpg

相似文献

1
Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap).非小细胞肺癌中的突变发生率和一致性:基于种族和组织学的荟萃分析(mutMap)。
Ann Oncol. 2013 Sep;24(9):2371-6. doi: 10.1093/annonc/mdt205. Epub 2013 May 30.
2
Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations.检测具有 EGFR 突变相关临床特征的非小细胞肺癌患者中的 EML4-ALK 融合基因。
Genes Chromosomes Cancer. 2012 Oct;51(10):925-32. doi: 10.1002/gcc.21976. Epub 2012 Jun 27.
3
Hot spot mutations in Finnish non-small cell lung cancers.芬兰非小细胞肺癌中的热点突变
Lung Cancer. 2016 Sep;99:102-10. doi: 10.1016/j.lungcan.2016.06.024. Epub 2016 Jun 27.
4
Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer.208 例中国非小细胞肺癌患者中 EML4-ALK 融合基因的临床意义及其与 EGFR 和 KRAS 基因突变的关系。
PLoS One. 2013;8(1):e52093. doi: 10.1371/journal.pone.0052093. Epub 2013 Jan 14.
5
Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.转移性肺腺癌中PIK3CA突变的检测,包括外显子4中一种新的V344G突变:115例细针穿刺抽吸活检病例的回顾性研究
Cancer Cytopathol. 2016 Jul;124(7):485-92. doi: 10.1002/cncy.21714. Epub 2016 Mar 23.
6
Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status.基于组织学和吸烟状况,鉴定非小细胞肺癌患者亚组中富集的驱动基因改变。
PLoS One. 2012;7(6):e40109. doi: 10.1371/journal.pone.0040109. Epub 2012 Jun 29.
7
[Relationship between EGFR and KRAS mutations and prognosis in Chinese patients with non-small cell lung cancer: a mutation analysis with real-time polymerase chain reaction using scorpion amplification refractory mutation system].中国非小细胞肺癌患者中表皮生长因子受体(EGFR)和 Kirsten 大鼠肉瘤病毒癌基因(KRAS)突变与预后的关系:使用蝎形扩增不应性突变系统的实时聚合酶链反应突变分析
Zhonghua Bing Li Xue Za Zhi. 2012 Oct;41(10):652-6. doi: 10.3760/cma.j.issn.0529-5807.2012.10.002.
8
PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers.PTEN 基因突变与非小细胞肺癌中 EGFR、ERBB2、KRAS 和 TP53 基因突变的关系。
Lung Cancer. 2010 Sep;69(3):279-83. doi: 10.1016/j.lungcan.2009.11.012. Epub 2009 Dec 16.
9
Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.磷酸肌醇 3-激酶催化亚单位α和 KRAS 突变是晚期非小细胞肺癌患者对表皮生长因子受体酪氨酸激酶抑制剂治疗产生耐药的重要预测因子。
J Thorac Oncol. 2011 Apr;6(4):707-15. doi: 10.1097/JTO.0b013e31820a3a6b.
10
Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.从不吸烟的非小细胞肺癌患者中,携带 EGFR 或 KRAS 突变或 ALK 重排的患者具有独特的临床特征和结局。
Cancer. 2012 Feb 1;118(3):729-39. doi: 10.1002/cncr.26311. Epub 2011 Jun 30.

引用本文的文献

1
A real-world pharmacovigilance study of FDA Adverse Event Reporting System events for gefitinib and docetaxel.一项针对吉非替尼和多西他赛的美国食品药品监督管理局不良事件报告系统事件的真实世界药物警戒研究。
Eur J Clin Pharmacol. 2025 Sep 6. doi: 10.1007/s00228-025-03905-8.
2
Refining treatment strategies for non-small cell lung cancer lacking actionable mutations: insights from multi-omics studies.完善缺乏可靶向突变的非小细胞肺癌的治疗策略:多组学研究的见解
Br J Cancer. 2025 Aug 23. doi: 10.1038/s41416-025-03139-6.
3
Deep mutational scanning reveals EGFR mutations conferring resistance to the 4th-generation EGFR tyrosine kinase inhibitor BLU-945.

本文引用的文献

1
Comprehensive genomic characterization of squamous cell lung cancers.全面基因组特征分析鳞状细胞肺癌
Nature. 2012 Sep 27;489(7417):519-25. doi: 10.1038/nature11404. Epub 2012 Sep 9.
2
Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status.基于组织学和吸烟状况,鉴定非小细胞肺癌患者亚组中富集的驱动基因改变。
PLoS One. 2012;7(6):e40109. doi: 10.1371/journal.pone.0040109. Epub 2012 Jun 29.
3
Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing.
深度突变扫描揭示了赋予对第四代EGFR酪氨酸激酶抑制剂BLU-945耐药性的EGFR突变。
NPJ Precis Oncol. 2025 Aug 20;9(1):294. doi: 10.1038/s41698-025-01086-2.
4
ATR expression as a prognostic biomarker in -mutated non-small cell lung cancer.ATR表达作为KRAS突变型非小细胞肺癌的预后生物标志物。 (你提供的原文中“-mutated”这里应该是有个具体基因如“KRAS”等缺失了,我按照补充完整后的意思翻译了,如果不是这样请根据实际情况调整)
J Thorac Dis. 2025 Jul 31;17(7):5197-5209. doi: 10.21037/jtd-2025-1113. Epub 2025 Jul 29.
5
Literature review of advances and challenges in mutant non-small cell lung cancer.突变型非小细胞肺癌进展与挑战的文献综述
Transl Lung Cancer Res. 2025 Jul 31;14(7):2799-2820. doi: 10.21037/tlcr-2025-164. Epub 2025 Jul 15.
6
First-Line Osimertinib for EGFR-Mutated Squamous Cell Lung Carcinoma: A Case Report.一线奥希替尼治疗表皮生长因子受体(EGFR)突变的肺鳞状细胞癌:病例报告
Cancer Rep (Hoboken). 2025 Jul;8(7):e70273. doi: 10.1002/cnr2.70273.
7
Molecular Diagnosis, Clinical Trial Representation, and Precision Medicine in Minority Patients with Oncogene-Driven Lung Cancer.分子诊断、临床试验表征与癌基因驱动肺癌少数族裔患者的精准医学
Cancers (Basel). 2025 Jun 11;17(12):1950. doi: 10.3390/cancers17121950.
8
The Genomic Landscape of Romanian Non-Small Cell Lung Cancer Patients: The Insights from Routine NGS Testing with the Oncomine Dx Target Panel at the PATHOS Molecular Pathology Laboratory.罗马尼亚非小细胞肺癌患者的基因组图谱:PATHOS分子病理学实验室使用Oncomine Dx靶向检测板进行常规NGS检测的见解
Cancers (Basel). 2025 Jun 11;17(12):1947. doi: 10.3390/cancers17121947.
9
FHL2 facilitates LUSC growth and therapy resistance through PI3K/AKT/mTOR activation.FHL2通过激活PI3K/AKT/mTOR促进肺鳞状细胞癌的生长和治疗抗性。
J Biol Chem. 2025 Jun 6;301(7):110332. doi: 10.1016/j.jbc.2025.110332.
10
Evolution of structure-guided drug design strategies targeting mutations in codon 12 of KRAS.针对KRAS基因第12密码子突变的结构导向药物设计策略的演变
RSC Med Chem. 2025 May 26. doi: 10.1039/d5md00169b.
使用全外显子组测序鉴定非小细胞肺癌中的体细胞突变。
Carcinogenesis. 2012 Jul;33(7):1270-6. doi: 10.1093/carcin/bgs148. Epub 2012 Apr 17.
4
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.厄洛替尼对比标准化疗用于治疗欧洲晚期 EGFR 突变阳性非小细胞肺癌患者的一线治疗(EURTAC):一项多中心、开放标签、随机、3 期临床试验。
Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26.
5
A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.全基因组和转录组测序揭示肺腺癌中存在一个转化的 KIF5B 和 RET 基因融合。
Genome Res. 2012 Mar;22(3):436-45. doi: 10.1101/gr.133645.111. Epub 2011 Dec 22.
6
Genotyping non-small cell lung cancer (NSCLC) in Latin America.对拉丁美洲的非小细胞肺癌(NSCLC)进行基因分型。
J Thorac Oncol. 2011 Nov;6(11):1955-9. doi: 10.1097/JTO.0b013e31822f655f.
7
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.厄洛替尼对比化疗用于治疗晚期 EGFR 突变阳性非小细胞肺癌患者的一线治疗(OPTIMAL、CTONG-0802):一项多中心、开放标签、随机、III 期研究。
Lancet Oncol. 2011 Aug;12(8):735-42. doi: 10.1016/S1470-2045(11)70184-X. Epub 2011 Jul 23.
8
The genomics of lung adenocarcinoma: opportunities for targeted therapies.肺腺癌的基因组学:靶向治疗的机遇
Genes Cancer. 2010 Dec;1(12):1200-10. doi: 10.1177/1947601911407324.
9
Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports.表皮生长因子受体突变非小细胞肺癌患者使用吉非替尼的疗效:已发表报告的汇总分析。
Cancer Sci. 2011 May;102(5):1032-7. doi: 10.1111/j.1349-7006.2011.01887.x. Epub 2011 Feb 28.
10
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.频繁且局灶性 FGFR1 扩增与鳞状细胞肺癌中可治疗的 FGFR1 依赖性相关。
Sci Transl Med. 2010 Dec 15;2(62):62ra93. doi: 10.1126/scitranslmed.3001451.